These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36983671)

  • 21. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
    Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
    Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
    Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
    Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin transporter pharmacogenomics: insights into drug disposition-where are we now?
    Chan P; Shao L; Tomlinson B; Zhang Y; Liu ZM
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1149-1159. PubMed ID: 30375241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disposition of metformin: variability due to polymorphisms of organic cation transporters.
    Zolk O
    Ann Med; 2012 Mar; 44(2):119-29. PubMed ID: 21366511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic studies update in type 2 diabetes mellitus.
    Singh S; Usman K; Banerjee M
    World J Diabetes; 2016 Aug; 7(15):302-15. PubMed ID: 27555891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function.
    Duong JK; Kumar SS; Kirkpatrick CM; Greenup LC; Arora M; Lee TC; Timmins P; Graham GG; Furlong TJ; Greenfield JR; Williams KM; Day RO
    Clin Pharmacokinet; 2013 May; 52(5):373-84. PubMed ID: 23475568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics of drug transporters.
    Franke RM; Gardner ER; Sparreboom A
    Curr Pharm Des; 2010; 16(2):220-30. PubMed ID: 19835554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of solute carrier transporter gene polymorphisms on serum creatinine concentrations in healthy volunteers.
    Yokoyama S; Nakagawa J; Kudo M; Aiuchi N; Seito T; Isida M; Mikami T; Ihara K; Nakaji S; Niioka T
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01048. PubMed ID: 36594679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients.
    He R; Zhang D; Lu W; Zheng T; Wan L; Liu F; Jia W
    Diabetes Res Clin Pract; 2015 Jul; 109(1):57-63. PubMed ID: 26004431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping of biguanide transporters in human fat cells and their impact on lipolysis.
    Arner P; Kulyté A; Batchelor K; Laurencikiene J; Livingston J; Rydén M
    Diabetes Obes Metab; 2018 Oct; 20(10):2416-2425. PubMed ID: 29862627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.
    Grün B; Kiessling MK; Burhenne J; Riedel KD; Weiss J; Rauch G; Haefeli WE; Czock D
    Br J Clin Pharmacol; 2013 Nov; 76(5):787-96. PubMed ID: 23305245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin.
    Chen EC; Liang X; Yee SW; Geier EG; Stocker SL; Chen L; Giacomini KM
    Mol Pharmacol; 2015 Jul; 88(1):75-83. PubMed ID: 25920679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of SLC22A2 (rs201919874) and SLC47A2 (rs138244461) genetic variants on Metformin Pharmacokinetics in Pakistani T2DM patients.
    Moeez S; Khalid Z; Jalil F; Irfan M; Ismail M; Arif MA; Niazi R; Khalid S
    J Pak Med Assoc; 2019 Feb; 69(2):155-163. PubMed ID: 30804576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of the SLC22A1, SLC22A2, and SLC22A3 genes encoding organic cation transporters with diabetic nephropathy and hypertension.
    Sallinen R; Kaunisto MA; Forsblom C; Thomas M; Fagerudd J; Pettersson-Fernholm K; Groop PH; Wessman M;
    Ann Med; 2010 May; 42(4):296-304. PubMed ID: 20429798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the rs3088442 G>A SLC22A3 Gene Polymorphism and the Role of microRNA 147 in Groups of Adult Pakistani Populations With Type 2 Diabetes in Response to Metformin.
    Moeez S; Riaz S; Masood N; Kanwal N; Arif MA; Niazi R; Khalid S
    Can J Diabetes; 2019 Mar; 43(2):128-135.e3. PubMed ID: 30297296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
    Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
    Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
    Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics-based population pharmacokinetic analysis of gabapentin in patients with chronic pain: Effect of OCT2 and OCTN1 gene polymorphisms.
    Yamamoto PA; Benzi JRL; Azeredo FJ; Dach F; Ianhez Júnior E; Zanelli CF; de Moraes NV
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):266-272. PubMed ID: 30192429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.
    Sam WJ; Roza O; Hon YY; Alfaro RM; Calis KA; Reynolds JC; Yanovski JA
    J Clin Pharmacol; 2017 Feb; 57(2):219-229. PubMed ID: 27407018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Kuss O; Müssig K; Burkart V; Szendroedi J; Kotzka J; Knebel B; Al-Hasani H; Roden M;
    Diabetologia; 2019 Feb; 62(2):286-291. PubMed ID: 30413829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.